<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316482</url>
  </required_header>
  <id_info>
    <org_study_id>LEUPLIN3M</org_study_id>
    <nct_id>NCT03316482</nct_id>
  </id_info>
  <brief_title>Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty</brief_title>
  <official_title>A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jin Soon Hwang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, open-label, prospective study to evaluate the safety and efficacy of&#xD;
      leuprorelin acetate DPS (Leuplin DPS) treatment quarterly in patients with central precocious&#xD;
      puberty&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type and design of study (eg, parallel, crossover, double-blind, open, superiority,&#xD;
      noninferiority).Blinding measures taken to minimize bias (eg, &quot;single-blind; subjects receive&#xD;
      blinded study medication&quot;).&#xD;
&#xD;
      A single arm, multicenter, open-label, prospective study. Requirements for run-in or washout&#xD;
      of medication. Those who have been administered one of the following drugs within 2 weeks&#xD;
      before they start to participate in this study&#xD;
&#xD;
        -  Estrogens&#xD;
&#xD;
        -  Antiestrogens&#xD;
&#xD;
        -  Progesterones&#xD;
&#xD;
        -  Steroids&#xD;
&#xD;
        -  Oriental medicines&#xD;
&#xD;
      Description of population to be studied (eg, adults with chronic heart failure and ejection&#xD;
      fraction below 40% or subjects with uncontrolled, long-term type 2 diabetes).&#xD;
&#xD;
      Children with central precocious puberty&#xD;
&#xD;
        -  Inclusion Criteria.&#xD;
&#xD;
             1. Female children aged '≥ 4 years ~ &lt; 9 years (8 years plus 364 days)&#xD;
&#xD;
             2. Those who fall under Tanner stage 2 at least (on condition that they started to&#xD;
                have breast budding under the age of 8)&#xD;
&#xD;
             3. Female children who showed pubertal LH response to GnRH stimulation test (peak ≥&#xD;
                7mIU/mL)&#xD;
&#xD;
             4. Those whose bone age increased by one year or more compared to their chronological&#xD;
                age&#xD;
&#xD;
             5. Subjects and their guardians who gave written consent to participate in this study&#xD;
&#xD;
        -  Exclusion Criteria.&#xD;
&#xD;
             1. Those whose bone age is 11 years and 6 months or older&#xD;
&#xD;
             2. Those secreting gonadal or adrenal cortex sex hormones in a non-LH-dependent manner&#xD;
&#xD;
             3. Those who have anaphylaxis to the IP or synthetic LHRH, or LHRH derivative&#xD;
&#xD;
             4. Those who have received GnRH analog treatment&#xD;
&#xD;
             5. Those who require treatment likely to influence the hypothalamic-pituitary-gonadal&#xD;
                axis during the study period&#xD;
&#xD;
             6. Those receiving growth hormone&#xD;
&#xD;
             7. Those who are suspected of or diagnosed with malignant tumor&#xD;
&#xD;
             8. Patients with severe renal failure or hepatic failure, whose participation in this&#xD;
                study is impossible in the investigator's opinion&#xD;
&#xD;
             9. Those who have been administered one of the following drugs within 2 weeks before&#xD;
                they started to participate in this study, or who are expected to be administered&#xD;
                during the study period&#xD;
&#xD;
                  -  Estrogens&#xD;
&#xD;
                  -  Antiestrogens&#xD;
&#xD;
                  -  Progesterones&#xD;
&#xD;
                  -  Steroids&#xD;
&#xD;
                  -  Oriental medicines&#xD;
&#xD;
            10. Those who have participated in another clinical study within 90 days from the date&#xD;
                when the IP was administered&#xD;
&#xD;
            11. Those who are found to be ineligible for this study in the investigator's opinion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2015</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 29, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Leuprorelin treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage(%) of subjects with inhibition of LH response (peak &lt;3mIU/mL)</measure>
    <time_frame>at 24 weeks</time_frame>
    <description>Percentage(%) of subjects with inhibition of LH response (peak &lt;3mIU/mL) maintained upon GnRH stimulation test at 12, 24, and 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LH peak/FSH ratio maintained to be &lt;1 upon</measure>
    <time_frame>at 12, 24, and 48 weeks</time_frame>
    <description>Percentage(%) of subjects with a LH peak/FSH ratio maintained to be &lt;1 upon GnRH stimulation test at 12, 24, and 48 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Central Precocious Puberty</condition>
  <arm_group>
    <arm_group_label>Leuplin DPS 11.25mg s.c. every 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuplin DPS 11.25mg</intervention_name>
    <description>Leuplin DPS 11.25mg s.c. every 12 weeks</description>
    <arm_group_label>Leuplin DPS 11.25mg s.c. every 12 weeks</arm_group_label>
    <other_name>injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female children aged '≥ 4 years ~ &lt; 9 years (8 years plus 364 days)&#xD;
&#xD;
          2. Those who fall under Tanner stage 2 at least (on condition that they started to have&#xD;
             breast budding under the age of 8)&#xD;
&#xD;
          3. Female children who showed pubertal LH response to GnRH stimulation test (peak ≥&#xD;
             7mIU/mL)&#xD;
&#xD;
          4. Those whose bone age increased by one year or more compared to their chronological age&#xD;
&#xD;
          5. Subjects and their guardians who gave written consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those whose bone age is 11 years and 6 months or older&#xD;
&#xD;
          2. Those secreting gonadal or adrenal cortex sex hormones in a non-LH-dependent manner&#xD;
&#xD;
          3. Those who have anaphylaxis to the IP or synthetic LHRH, or LHRH derivative&#xD;
&#xD;
          4. Those who have received GnRH analog treatment&#xD;
&#xD;
          5. Those who require treatment likely to influence the hypothalamic-pituitary-gonadal&#xD;
             axis during the study period&#xD;
&#xD;
          6. Those receiving growth hormone&#xD;
&#xD;
          7. Those who are suspected of or diagnosed with malignant tumor&#xD;
&#xD;
          8. Patients with severe renal failure or hepatic failure, whose participation in this&#xD;
             study is impossible in the investigator's opinion&#xD;
&#xD;
          9. Those who have been administered one of the following drugs within 2 weeks before they&#xD;
             started to participate in this study, or who are expected to be administered during&#xD;
             the study period&#xD;
&#xD;
               -  Estrogens&#xD;
&#xD;
               -  Antiestrogens&#xD;
&#xD;
               -  Progesterones&#xD;
&#xD;
               -  Steroids&#xD;
&#xD;
               -  Oriental medicines&#xD;
&#xD;
         10. Those who have participated in another clinical study within 90 days from the date&#xD;
             when the IP was administered&#xD;
&#xD;
         11. Those who are found to be ineligible for this study in the investigator's opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Soon Hwang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajoun university hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hwang, Jin Soon</name>
      <address>
        <city>Suwon-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jin Soon Hwang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

